US Patent Issued to CENTESSA PHARMACEUTICALS (UK) on July 21 for "Anti-PD-L1 antibodies" (British Inventor)

ALEXANDRIA, Va., July 21 -- United States Patent no. 12,686,717, issued on July 21, was assigned to CENTESSA PHARMACEUTICALS (UK) Ltd. (Altrincham, Great Britain).

"Anti-PD-L1 antibodies" was invented by Steve Holmes (London).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to antigen binding molecules, particularly antibodies, fragments and variants thereof, that bind to the programmed death-ligand 1 (PD-L1) in a pH-dependant manner, competing with PD-L1 binding to the inhibitory receptor programmed death 1 polypeptide (PD-1) and co-stimulatory molecule CD80, and the use of said antigen binding molecules in treating and/or preventing diseases such as cancer."

The patent was filed...